Acumen Pharmaceuticals, Inc.

NasdaqGS:ABOS Stok Raporu

Piyasa değeri: US$170.9m

Acumen Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Acumen Pharmaceuticals' CEO is Dan O'Connell, appointed in Dec 2014, has a tenure of 9.92 years. total yearly compensation is $3.93M, comprised of 15.2% salary and 84.8% bonuses, including company stock and options. directly owns 0.042% of the company’s shares, worth $72.51K. The average tenure of the management team and the board of directors is 3 years and 6.1 years respectively.

Anahtar bilgiler

Dan O'Connell

İcra Kurulu Başkanı

US$3.9m

Toplam tazminat

CEO maaş yüzdesi15.2%
CEO görev süresi9.9yrs
CEO sahipliği0.04%
Yönetim ortalama görev süresi3yrs
Yönetim Kurulu ortalama görev süresi6.1yrs

Son yönetim güncellemeleri

Recent updates

Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?

Aug 05
Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?

Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's

Jul 30

Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?

Apr 21
Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?

Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

Sep 21
Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Feb 01
We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Oct 16
Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Acumen Pharma at 11-month high on rivals’ Alzheimer’s data

Sep 28

Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate

Jun 30

We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

May 10
We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Jan 07
We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Oct 01
Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

CEO Tazminat Analizi

Dan O'Connell'un ücretlendirmesi Acumen Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$65m

Mar 31 2024n/an/a

-US$56m

Dec 31 2023US$4mUS$598k

-US$52m

Sep 30 2023n/an/a

-US$49m

Jun 30 2023n/an/a

-US$46m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$3mUS$570k

-US$43m

Sep 30 2022n/an/a

-US$38m

Jun 30 2022n/an/a

-US$32m

Mar 31 2022n/an/a

-US$83m

Dec 31 2021US$1mUS$525k

-US$101m

Sep 30 2021n/an/a

-US$93m

Jun 30 2021n/an/a

-US$92m

Mar 31 2021n/an/a

-US$32m

Dec 31 2020US$336kUS$240k

-US$7m

Tazminat ve Piyasa: Dan's total compensation ($USD3.93M) is above average for companies of similar size in the US market ($USD1.48M).

Tazminat ve Kazançlar: Dan's compensation has increased whilst the company is unprofitable.

CEO

Dan O'Connell (54 yo)

9.9yrs

Görev süresi

US$3,930,011

Tazminat

Mr. Daniel J. O’Connell, also known as Dan, MBA was a Key Advisor at Acidophil, LLC. He served as President until February 01, 2024 and serves as Chief Executive Officer of Acumen Pharmaceuticals, Inc. si...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Daniel O'Connell
CEO & Director9.9yrsUS$3.93m0.042%
$ 72.5k
Matt Zuga
CFO & Chief Business Officer3.5yrsUS$1.61m0.14%
$ 236.4k
Derek Meisner
Chief Legal Officer & Corporate Secretary2.2yrsUS$1.48m0%
$ 0
James Doherty
President & Chief Development Officerless than a yearVeri yokVeri yok
Grant Krafft
Co-Founder28.8yrsUS$42.00kVeri yok
Caleb Finch
Co-Founderno dataVeri yokVeri yok
William Klein
Co-Founderno dataVeri yokVeri yok
Russell Barton
Chief Operating Officer3.8yrsUS$223.68k0.16%
$ 275.6k
Kelly Carranza
Vice President1.3yrsVeri yokVeri yok
Alex Braun
VP & Head of Investor Relations2.2yrsVeri yokVeri yok
Robyn Moxon
Associate Director of Communications2.5yrsVeri yokVeri yok
Julie Bockenstette
Executive VP & Head of Human Resources3.8yrsVeri yokVeri yok

3.0yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: ABOS's management team is considered experienced (3 years average tenure).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Daniel O'Connell
CEO & Director18.6yrsUS$3.93m0.042%
$ 72.5k
Michael Weiner
Member of Clinical & Scientific Advisory Boardno dataVeri yokVeri yok
Colin Masters
Member of Clinical & Scientific Advisory Boardno dataVeri yokVeri yok
Jeffrey Cummings
Member of Clinical & Scientific Advisory Boardno dataVeri yokVeri yok
Sean Stalfort
Independent Chairman of the Board6.1yrsUS$173.52k0.51%
$ 864.7k
Kimberlee Drapkin
Independent Director2.6yrsUS$152.27k0%
$ 0
Steven DeKosky
Member of Clinical & Scientific Advisory Boardno dataVeri yokVeri yok
Jeffrey L. Ives
Independent Director10.5yrsUS$141.02k0%
$ 0
Reisa Sperling
Member of Clinical & Scientific Advisory Boardno dataVeri yokVeri yok
Cynthia Lemere
Member of Clinical & Scientific Advisory Boardno dataVeri yokVeri yok
Laura Stoppel
Independent Director4yrsUS$147.52k0%
$ 0
Stephen Salloway
Member of Clinical & Scientific Advisory Boardno dataVeri yokVeri yok

6.1yrs

Ortalama Görev Süresi

64.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ABOS's board of directors are considered experienced (6.1 years average tenure).